• Noram Lithium (NRM) announced the summary results of a PEA for the high-grade lithium deposit at its wholly-owned Zeus Lithium Project in Nevada
  • Highlights include $1.299 billion NPV and gross revenue of $303.4 Million/year
  • Noram Lithium is a Canadian-based junior exploration company focused on developing lithium deposits
  • The company’s primary business is the Zeus Lithium Project (Zeus) in Clayton Valley, Nevada
  • Noram Lithium Corp. (NRM) opened trading at C$0.91 per share

Noram Lithium (NRM) announced the summary results of a PEA for the high-grade lithium deposit at its wholly-owned Zeus Lithium Project.

The project is located less than 1 mile from the only lithium production facility in the United States.

PEA highlights (US$)

  • $1.299 billion Net Present Value (NPV)
  • 31 per cent Internal Rate of Return (IRR)
  • Estimated initial CAPEX of $528 million with after-tax payback period of 3.23 years
  • Gross revenue of $303.4 million/year
  • Operating cost (OPEX) of $3,355.30/tonne Lithium Carbonate Equivalent (LCE) with a break-even price of $4016.6/tonne LCE LOM
  • Estimated 40-year mine life

Peter Ball, President of Noram Lithium sat down with Dave Jackson to discuss the news.

Noram Lithium is a Canadian-based junior exploration company focused on developing lithium deposits and becoming a low-cost supplier. The company’s primary business is the Zeus Lithium Project (Zeus) in Clayton Valley, Nevada.

Noram Lithium Corp. (NRM) opened trading at C$0.91 per share.

More From The Market Online
The Market Online Video

Exploration company provides project portfolio update

Banyan Gold Corp. (TSXV:BYN) is focused on exploration and advancing and de-risking its AurMac Gold Project in the Yukon.
stock market down

@ the Bell: Industrials weakness snaps TSX win streak

Industrials led decliners, followed by financials, to snap the TSX’s five-day win streak while energy, utilities and mining provided gains.

This life sciences company is gearing up to treat long COVID  

Revive Therapeutics (CSE:RVV), a Toronto-based company, has immense potential to capitalize on treating long COVID symptoms.